Safety~Incidence of fever (temperature ≥39.0℃) within 42 days after the IP administration~Incidence of fever (temperature ≥39.0℃) within 7 days after the IP administration~Solicited local/systemic AEs occurred within 7 days after the IP administration Unsolicited adverse events that occurred within 42 days after the IP administration~Serious adverse events that occurred within 1 year after the IP administration~Vital signs and physical examinations~Efficacy (Immunogenicity)~-GMT(Geometric Mean Titer) and GMR(Geometric Mean Ratio(fold change))measured by the glycoprotein enzyme-linked immunosorbent assay (gpELISA) at before and 42 days after the IP administration~Exploratory assessment~GMV and GMR of VZV-CMI response measured by INF-r ELISPOT before and 42 days after the IP administration GMV and GMR of VZV-CMI response measured by INF-r ELISPOT at before and 42 days after the IP administration~GMT and GMR antibody titer measured by gpELISA assay before and after the IP administration for 3 years GMT and GMR of the antibody titer measured by gpELISA at before and after the IP administration for 3 years~Varicella-like rash and Varicella-zoster virus genotyping analysis occurred after IP administration for 3 years
Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination~Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination